RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Add like
Add dislike
Add to saved papers

Metoclopramide effect on faltering milk production by mothers of premature infants.

Pediatrics 1986 October
Metoclopramide treatment has been shown to augment milk production by stimulating prolactin secretion in women in whom lactational insufficiency develops after a full-term pregnancy. The effect of metoclopramide therapy in 23 women who were delivered of premature infants (birth weight 1,314 +/- 115 g, gestational age 30.4 +/- 0.7 weeks) and who were having difficulty maintaining milk production with milk expression was evaluated. Each woman had noted a gradual decrease in the total daily volume of expressed milk during the first several weeks of lactation. Maternal metoclopramide therapy was started at a mean of 32.0 +/- 3.7 days postpartum, after a review of diet and milk expression technique and an increase in the number of expressions per day failed to increase milk production. Daily milk production increased significantly from 93.3 +/- 18.0 mL/d to 197.4 +/- 32.3 mL/d between the first and seventh day of therapy. This increase was associated with significantly increased basal serum prolactin levels, from 18.1 +/- 3.3 ng/mL to 121.8 +/- 21.5 ng/mL. Although milk expression resulted in a variable increase in serum prolactin levels prior to metoclopramide treatment, milk expression did not produce any additional prolactin response in the treated women, with mean basal levels of 157.8 +/- 15.4 ng/mL v mean peak levels of 144.5 +/- 12.2 ng/mL. No major side effects were reported by the women, and no untoward effects were noted in the infants fed milk expressed while their mothers were being treated with metoclopramide.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app